secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001558370-23-002988
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager reports Q4 2022 net loss of $23.6M; highlights partnerships with Neurocrine, Novartis, Pfizer
--------------------------------------------------------------------------------

- Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.
- Neurocrine collaboration closed Jan 2023: $175M upfront, up to $4.2B milestones, plus royalties and opt-in for GBA1 program.
- Novartis exercised capsid license options for two CNS targets (March 2023): $25M payment, up to $600M milestones plus royalties.
- Pfizer exercised capsid option in Oct 2022: $10M payment, up to $290M milestones plus royalties.
- Cash $118.8M at Dec 31, 2022; expected into 2025 after deals. Pipeline: VY-TAU01 selected, SOD1 candidate in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/0001558370-23-002988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/vygr-20230307x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer